Zhang Hongliang, Yu Yiyang, Wang Jun, Han Yu, Ren Tingting, Huang Yi, Chen Chenglong, Huang Qingshan, Wang Wei, Niu Jianfang, Lou Jingbing, Guo Wei
Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, People's Republic of China.
Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.
Cancer Cell Int. 2021 Apr 1;21(1):192. doi: 10.1186/s12935-021-01893-0.
Osteosarcoma (OS) is the most common primary malignant bone tumor in young people. Tumor-associated macrophages (TAMs) have been reported to play an important role in the development of osteosarcoma. However, the detailed molecular mechanisms remain largely unknown and need to be elucidated. Recently, exosomes have been reported as the crucial mediator between tumor cells and the tumor microenvironment. And a lot of lncRNAs have been reported to act as either oncogenes or tumor suppressors in osteosarcoma. In this research, we aim to explore the role of macrophages-derived exosomal lncRNA in osteosarcoma development and further elucidated the potential molecular mechanisms involved.
TAMs were differentiated from human mononuclear cells THP-1, and a high-throughput microarray assay was used to analyze the dysregulated lncRNAs and miRNAs in osteosarcoma cells co-cultured with macrophages-derived exosomes. Western blot, qRT-PCR assays, and Dual-luciferase reporter assay were used to verify the interaction among LIFR-AS1, miR-29a, and NFIA. Cck-8, EdU, colony formation assay, wound-healing, and transwell assay were performed to explore the characterize the proliferation and metastasis ability of OS cells. And qPCR, Western blots, immunohistochemistry, and cell immunofluorescence were used to detect the expression of relative genes or proteins.
In this study, we found that THP-1-induced macrophage-derived exosomes could facilitate osteosarcoma cell progression both in vitro and in vivo. Then, the results of the high-throughput microarray assay showed that LIFR-AS1 was highly expressed and miR-29a was lowly expressed. Furthermore, LIFR-AS1 was identified as a miR-29a sponge, and NFIA was validated as a direct target of miR-29a. Functional assays demonstrated that knockdown of exosomal LIFR-AS1 could attenuate the promotion effects of macrophages-derived exosomes on osteosarcoma cell progression and miR-29a inhibition could reserve the effect of LIFR-AS1-knockdown exosomes. Correspondingly, NFIA-knockdown could partially reverse the tumor inhibition effect of miR-29a on osteosarcoma cells.
Taken together, macrophages-derived exosomal lncRNA LIFR-AS1 can promote osteosarcoma cell proliferation, invasion, and restrain cell apoptosis via miR-29a/NFIA axis, which can act as a potential novel therapeutic target for osteosarcoma therapy.
骨肉瘤(OS)是年轻人中最常见的原发性恶性骨肿瘤。据报道,肿瘤相关巨噬细胞(TAM)在骨肉瘤的发展中起重要作用。然而,详细的分子机制在很大程度上仍然未知,需要阐明。最近,外泌体被报道为肿瘤细胞与肿瘤微环境之间的关键介质。并且有许多lncRNA在骨肉瘤中被报道为癌基因或肿瘤抑制因子。在本研究中,我们旨在探讨巨噬细胞来源的外泌体lncRNA在骨肉瘤发展中的作用,并进一步阐明其潜在的分子机制。
TAM由人单核细胞THP-1分化而来,采用高通量微阵列分析来分析与巨噬细胞来源的外泌体共培养的骨肉瘤细胞中失调的lncRNA和miRNA。采用蛋白质免疫印迹法、qRT-PCR检测法和双荧光素酶报告基因检测法验证LIFR-AS1、miR-29a和NFIA之间的相互作用。进行Cck-8、EdU、集落形成实验、伤口愈合实验和Transwell实验来探究骨肉瘤细胞的增殖和转移能力。并采用qPCR、蛋白质免疫印迹法、免疫组织化学和细胞免疫荧光法检测相关基因或蛋白质的表达。
在本研究中,我们发现THP-1诱导的巨噬细胞来源的外泌体在体外和体内均可促进骨肉瘤细胞进展。然后,高通量微阵列分析结果显示LIFR-AS1高表达而miR-29a低表达。此外,LIFR-AS1被鉴定为miR-29a的海绵,NFIA被验证为miR-29a的直接靶点。功能实验表明,敲低外泌体LIFR-AS1可减弱巨噬细胞来源的外泌体对骨肉瘤细胞进展的促进作用,抑制miR-29a可恢复敲低LIFR-AS1的外泌体的作用。相应地,敲低NFIA可部分逆转miR-29a对骨肉瘤细胞的肿瘤抑制作用。
综上所述,巨噬细胞来源的外泌体lncRNA LIFR-AS1可通过miR-29a/NFIA轴促进骨肉瘤细胞增殖、侵袭并抑制细胞凋亡,这可作为骨肉瘤治疗的潜在新靶点。